EGFR and neoplasm: Furthermore, a previously described pharmacologic perturbation of EGFR endocytic trafficking results to be deleterious to EGFR-dependent tumor cells [20], and might eventually counteract GOF mutp53-mediated EGFR recycling and signaling [21].